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Abstract: This study aims at evaluating the importance of the two-component regulatory system VicRK to virulence of 
the horse pathogen Streptococcus equi subspecies equi and the potential of a vicK mutant as a live vaccine candidate using 
mouse infection models. The vicK gene was deleted by gene replacement. The vicK mutant is attenuated in virulence in 
both subcutaneous and intranasal infections in mice. vicK grows less slowly than the parent strain but retains the ability 
of S. equi to resist to phagocytosis by polymorphoneuclear leukocytes, suggesting that the vicK deletion causes growth de-
fect. vicK infection protects mice against reinfection with a wild-type S. equi strain. Intranasal vicK infection induces 
production of anti-SeM mucosal IgA and systemic IgG. These results indicate that VicRK is important to S. equi growth 
and virulence and suggest that vicK has the potential to be developed as a live S. equi vaccine. 
INTRODUCTION 
Bacterial pathogens produce many two-component regu-
latory systems to regulate gene expression by specific envi-
ronmental signals [1]. These systems consist of membrane 
protein sensors and cognate cytoplasmic response regulators. 
The regulator is phosphorylated by the sensor in response to 
a specific signal, activating or repressing the transcription of 
target genes. The two-component regulatory system VicRK 
or YycFG is specific for Gram-positive bacteria. The regula-
tor component VicR is essential in Bacillus subtilis [2], 
Staphylococcus aureus [3], and Streptococcus pneumoniae 
[4-5] but appears not to be essential in Streptococcus pyo-
genes [6]. The deletion of the vicK gene can be readily inac-
tivated in S. pneumoniae [7], Streptococcus mutans [8], and 
S. pyogenes [6] but not in B. subtilis [2] and S. aureus [3]. 
Conditional and unconditional vicRK mutants display vari-
ous phenotypes, including defects in morphology and cell 
wall synthesis, decreased competence, sensitivity to antibiot-
ics and fatty acids, defects in biofilm formation, and attenu-
ated virulence, growth defect, and sensitivity to osmotic 
pressure [3, 6, 8-11]. 
The vicRK system of Gram-positive bacterium Strepto-
coccus equi subspecies equi (S. equi) has not been studied. 
This pathogen causes equine strangles, a highly contagious 
purulent lymphadenitis [12-13]. The infection initially 
causes nasal discharge and fever and, then, leads to abscess 
formation in local lymph nodes, causing respiratory diffi-
culty. Although the infection at the lymph nodes cause mas-
sive infiltration of polymorphoneuclear leukocytes (PMNs) 
[14], S. equi resists phagocytosis by PMNs and rapidly mul-
tiplies, forming an abscess of large numbers of degenerating 
PMNs and long chains of S. equi [15]. The hyaluronic acid  
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capsule and S. equi M-like protein (SeM) are both required 
for the resistance to phagocytosis by PMNs [16-17]. Most 
horses recovered from strangles have immunity against S. 
equi reinfection for up to 5 years [18]. It is believed that the 
immunity is mediated by mucosal antibodies specific to SeM 
and other protective antigens. An intranasal vaccine made of 
live attenuated strain has been used in USA, which lacks the 
hyaluronic acid capsule, and various adverse effects, includ-
ing pharyngeal lymphadenopathy, limb edema, and bastard 
strangles abscesses, have been reported [15]. 
This study aims at evaluating the importance of VicRK to 
S. equi virulence and the potential of a vicK deletion mutant 
as a live vaccine using mouse infection models. We found 
that the vicK deletion attenuated S. equi virulence in mouse 
models of subcutaneous and intranasal infections and that 
infection with a vicK deletion mutant confers protection 
against subsequent infection with wild-type S. equi and in-
duces production of mucosal and systemic immunoglobins to 
SeM in nasal infection. 
MATERIALS AND METHODS 
Bacterial Strains and Growth 
S. equi strain SEM1 was isolated in 2003 from a horse 
with strangles in Montana, USA. SEM1 and its mutant were 
routinely grown in Todd-Hewitt broth supplemented with 
0.2% yeast extract (THY) in 5% CO2 at 37°C without and 
with 150 mg/liter spectinomycin, respectively.  
Generation of a vicK Deletion Mutant 
A  vicK deletion mutant (vicK) of S. equi SEM1 was 
generated by gene replacement (Fig. 1). The upstream and 
downstream flanking fragments of the deleted internal frag-
ment (bases 451-1282) of vicK were PCR-amplified using 
paired primers 5’- GAAGCTTCTTATGACTAAGGACAT-
CATTGGAAC-3’/5’-GAGATCTGGTGTAAGGTGAGTC 
ACTGTC-3’ and 5’-AGGATCCCCTTTACCATTGTG TTA 
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AC-3’, respectively. The PCR products of the upstream and 
downstream fragments were sequentially cloned into pGRV 
[19] at the HindIII/BglII and BamHI/SalI sites, respectively, 
to yield pGRV-vicK. pGRV-vicK was introduced into S. 
equi strain SEM1 by electroporation using the conditions 
described previously for S. pyogenes [6], and the sample was 
plated on THY agar plate with 150 mg/liter spectinomycin. 
The obtained colonies, which could be derived from a single 
or double crossover recombination, were screened by PCR 
using primers 5’-GAGACTGCTC AAAAGCAGCTC-3’ and 
5’-GATTTGACTCAATCAAGTAGC-3’ and DNA sequenc-
ing analyses to identify the desired deletion mutant. 
S. equi Growth in Rabbit Blood 
S. equi strains were harvested at the exponential growth 
phase, washed three times with pyrogen-free Dulbecco’s 
phosphate-buffered saline (DPBS), and inoculated at 2 x 10
4 
cfu/ml in heparinized rabbit blood. The samples were rotated 
end-to-end at 37°C for 4 h, and numbers of viable S. equi in 
the samples and actual inocula were determined by plating 
on THY agar. Growth factor is defined as the ratio of col-
ony-forming units (cfu) of each sample after 4-h incubation 
to cfu in the inoculum. 
Phagocytosis Assay 
Phagocytosis assay was performed as described previ-
ously [6, 20]. Briefly, S. equi SEM1 wild-type and vicK 
cells from exponential growth phase in THY were washed 
with phosphate-buffered saline (PBS) and labeled with 0.75 
g/mL FITC in PBS at 37°C for 20 min. The labeled bacte-
ria were washed and suspended at 1 x 10
9 cfu/ml in PBS. Ten 
μl of the labeled bacteria were mixed with 100 μl of non-
immune heparinized rabbit or horse blood and incubated 
with gentle shaking at 37°C for 5 or 15 min. The samples 
were immediately processed using an Immunolyse Kit 
(Beckman Coulter) according to the manufacturer’s protocol 
and analyzed by flow cytometry. The percentage of PMNs 
with fluorescent bacteria was used as a measure of phagocy-
tosis efficiency. 
Mouse Infections 
S. equi strains were harvested at exponential phase, 
washed with DPBS, and inoculated subcutaneously or intra-
nasally at inocula specified in figure legends into groups of 8 
female outbred CD-1 Swiss mice. Survival rates were exam-
ined daily for 20 days after inoculation. At the end of the 
intranasal infection experiment, blood was collected from the 
surviving mice via cardiac puncture, and the nasal wash flu-
ids were then obtained as follows. The trachea was perfo-
rated, a small tube was inserted into the opening, and the 
nasal cavity was slowly flushed with 1.0 ml DPBS through 
the tube. All animal procedures were approved by the Insti-
tutional Animal Care and Use Committee at Montana State 
University, Bozeman, USA.  
Enzyme-linked Immunosorbant Assay (ELISA) and 
Western Blotting Analysis  
Relative levels of anti-SeM IgG in sera of mice recovered 
from the intranasal S. equi infections were estimated by 
ELISA and Western blotting using a truncated recombinant 
SeM containing amino acids 38 to 260 (SeM
38-260) with de-
scribed procedures [21]. Briefly for ELISA, microtiter plates 
were coated overnight with SeM
38-260 at a concentration of 
0.25 g/well. The plates were washed four times with PBS 
containing 0.1% (vol/vol) Tween 20 (PBS-T), blocked with 
0.1% bovine albumin (BSA) in PBS-T for 2 h at room tem-
perature, and washed as described above. The plate was in-
cubated with 100 μl/well of mouse sera diluted at 1:100 to 
1:51200 in 0.1% BSA in PBS-T and washed as described 
above. The wells were incubated with goat anti-mouse IgG 
(H + L)-peroxidase conjugate (1:4,000 dilution). The plates 
were washed as described above and washed four times with 
PBS to remove Tween 20. The plates were developed with 
100 l/well of ABTS solution for 30 min and the absorbance 
was measured at 405 nm. Titers were determined by the 
geometric method. The presence of SeM
38-260-specific IgA in 
the nasal wash samples were determined by A405 in the 
ELISA assay as described above using 100 μl of 2-fold-
diluted nasal wash samples and goat anti-mouse IgA HRP 
conjugate (Bethyl Laboratories, Inc.). 
RESULTS 
S. equi vicK Deletion Mutant 
The S. equi vicRK genes were found by blasting the S. 
equi genome database (http://www.sanger.ac.uk/Projects/ 
S_equi) with the S. pyogenes vicRK sequence. Gene re-
placement strategy was used to generate vicK-deletion mu-
tant (Fig. 1A). The vector pGRV has two genes aad and cmR 
for selections with spectinomycin and chloramphenicol, re-
spectively. The two upstream and downstream flanking 
fragments of the internal vicK fragment from Tyr151 to 
Ser427 to be deleted were cloned at the upstream and down-
stream ends of the aad gene, respectively, resulting in sui-
cide plasmid pGRV-vicK. Single crossover between one 
flanking fragment in pGRV-vicK and the homologous re-
gion in the genome would lead to the insertion of the whole 
plasmid into S. equi genome, resulting in strains resistant to 
both spectinomycin and chloramphenicol. Double crossover 
at both of the flanking fragments would lead to the replace-
ment of the vicK internal fragment with the aad gene, result-
ing in vicK deletion strains with resistance only to spectino-
mycin. The colonies on spectinomycin agar plates were 
tested for resistance to chloramphenicol. Three putative 
vicK strains, which were spectinomycin-resistant and chlo-
ramphenicol-sensitive, were obtained. PCR analyses using 
the primers located beyond the deleted fragment resulted in 
the PCR product from these strains that were expectedly 
bigger than that from the wild-type strain because the replac-
ing fragment was bigger than the displaced vicK fragment 
(Fig. 1B). DNA sequencing confirmed the desired deletion. 
One deletion strain was randomly chosen for further charac-
terization. 
Growth of vicK in THY and Rabbit Blood 
The growth curve of the vicK mutant in THY displays a 
longer early growth phase and smaller slope in the exponen-
tial growth phase than that of the parent strain (Fig. 2A), 
indicating that the vicK deletion detrimentally affects S. equi 
growth. The effect of the deletion on S. equi growth in blood 
was also examined. The wild-type and vicK S. equi strains Streptococcus equi vicK Mutant  The Open Microbiology Journal, 2008, Volume 2    91 
were inoculated into 1 ml heparinized rabbit blood at an in-
oculum of approximately 20,000 cfu. The samples were in-
cubated for 4 h, and the numbers of the bacteria in the sam-
ples and inocula at time zero were determined by plating. 
The growth factors, the ratio of cfu in the sample at 4 h over 
cfu at time zero, were 250 and 66 for the wild type and 
vicK strains, respectively (Fig. 2B). Thus, the vicK mutant 
has significantly reduced ability to grow in rabbit blood (P < 
0.0001). 
No Effect of the vicK Deletion on Resistance of S. equi to 
Phagocytosis by PMNs 
To determine whether the vicK deletion affects the re-
sistance of S. equi to phagocytosis by PMNs, the phagocyto-
sis of wild-type and vicK bacteria by PMNs in non-immune 
horse and rabbit blood was compared. FITC-labeled wild-
type S. equi, vicK mutant, and S. pyogenes  spy1718::aad 
mutant were incubated with heparinized horse or rabbit 
blood for 5 and 15 min, and percentages of PMNs associated 
with fluorescent bacteria were quantified using flow cytome-
try analysis. The spy1718::aad mutant of S. pyogenes, which 
is no longer resistant to phagocytosis by PMNs, was used as 
a positive control in the assay. The percentages of PMNs 
with associated wild-type S. equi and spy1718::aad were low 
and high, respectively, indicating that the assay worked well 
to evaluate resistance of the bacteria to phagocytosis. There 
was no significant difference in the percentages of PMNs 
associated with wild-type and vicK bacteria at both time 
points and in both horse and rabbit blood (Fig. 3), indicating 
that the vicK mutant retains the ability of S. equi to resist to 
phagocytosis by PMNs. 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Association of wild-type and vicK bacteria with rabbit (A) 
and horse (B) PMNs. FITC-labeled bacteria (10
7 cfu) were incu-
bated with 100 μl heparinized blood at 37ºC for 5 or 15 min. Red 
blood cells were lysed using an Immunolyse kit, and percentages of 
PMNs with associated (bound and phagocytosed) bacteria deter-
mined by flow cytometry are presented. A S. pyogenes 
spy1718::aad mutant was included as a positive control. 
Attenuation of S. equi Virulence by vicK Deletion 
Group of 8 mice were subcutaneously inoculated with 1.1 
x 10
8 cfu wild-type or vicK mutant strains. Seven of the 8 
mice infected with the wild-type S. equi strain died, whereas 
7 of the 8 mice inoculated with vicK survived (Fig. 4A). 
The infection was performed in a model of intranasal infec-
 
 
 
 
 
 
 
 
 
 
Fig. (2). A) growth curves of wild-type and vicK strains in THY.  
Cultures at the exponential phase were inoculated into fresh THY, 
and OD600 was measured at the indicated times. B) growth of wild-
type and vicK strains in rabbit blood.  Approximately 2 x 10
4 cfu 
of each strain was inoculated into 1 ml blood in triplicate. Numbers 
of the bacteria in inocula and in the samples after end-to-end rota-
tion at 37ºC for 4 h were determined by plating.  The growth factor 
(cfu at 4 h/ cfu at 0 h) ± SD is presented. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Deletion of the vicK gene. A) schematic for vicK deletion 
by gene replacement. The two flanking fragments of the internal 
vicK fragment to be deleted were cloned into the up- and down-
stream ends of the aad gene in pGRV. The resulting plasmid 
pGRV-vicK was introduced into S. equi, and double crossover in 
the homologous regions between the plasmid and S. equi genome 
resulted in vicK mutants. B) PCR confirmation of the vicK dele-
tion. The picture shows agarose gel analysis of PCR reactions using 
mutant (lane vicK) or wild-type (lane wt) genomic DNA as tem-
plate and primers indicated by the arrows under the mutant genome. 
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tion as well. All the 8 mice infected with vicK survived, 
whereas 5 of the 8 mice infected with the wild-type S. equi 
strain died (Fig. 4B). These results indicate that the vicK 
deletion significantly attenuated S. equi virulence in both 
mouse models of subcutaneous (P = 0.0066) and nasal (P = 
0.0085) infections. 
 
 
 
 
 
 
 
 
 
 
 
Fig. (4). Attenuation of S. equi virulence by vicK deletion and pro-
tection of mice against wild-type S. equi infection conferred by 
preceding vicK infection. Groups of 8 CD-1 mice were inoculated 
subcutaneously (A) and intranasally (B) with 1.1 x 10
8 cfu of each 
strain, and survival rates were determined daily. Panel A also in-
cludes the results of the subcutaneous infection with 1.5 x 10
8 cfu 
of the wild-type strain on the 7 mice survived from the subcutane-
ous vicK infection (the open circles). 
vicK Infection Confers Protection of Mice against Rein-
fection with Wild-Type S. equi  
To test whether vicK infection confers immunity against 
S. equi infection, the seven mice recovered from the subcu-
taneous vicK infection was reinfected subcutaneously with 
1.5 x 10
8 cfu wild-type S. equi 30 days after the first infec-
tion and monitored for 18 days. Six of the 7 mice survived 
the reinfection (Fig. 4A), suggesting that the vicK infection 
induces immunity against S. equi infection. 
Intranasal vicK Infection Induces SeM-Specific Muco-
sal IgA and Systemic IgG 
To examine the humoral immune responses in the intra-
nasal vicK infection, nasal wash and serum samples were 
collected from the 8 mice infected intranasally with vicK 
and 3 surviving mice infected with the wild-type S. equi 30 
days after infection. Half of the nasal wash samples from the 
mice infected with vicK had similar levels of SeM
38-260-IgA 
reactivity with those from the mice infected with the wild-
type strains. Similarly, these 4 mice with higher IgA levels 
also had higher levels of SeM-specific systemic IgG (Fig. 
5B). Western blotting analysis was used to confirm the pres-
ence of SeM-specific IgG. The wild-type sera and 5 of the 8 
vicK samples had strong immunoreactions with SeM
38-260 
in Western blotting analysis (Fig. 5C). Thus, the vicK mu-
tant has the ability to induce mucosal and systemic immune 
responses, though there was host variation in these responses 
caused by vicK infection. 
 
 
 
 
 
 
 
 
 
Fig. (5). Assessment of SeM-specific mucosal IgA and systemic 
IgG production in mice with the intranasal S. equi infection by 
ELISA and Western immunoblot. Nasal wash and serum samples 
were collected from the surviving mice in the nasal infections with 
wild-type and vicK strains of Fig. 4B on day 30 after inoculation. 
A) immunoreactivity of SeM
38-260 with IgA in the nasal wash sam-
ples.  B) the reciprocal of anti-SeM
38-260 IgG titers in the serum 
samples. C) immunoblots demonstrating anti-SeM
38-260 IgG in the 
serum samples, which were diluted by 1:1000 in the assay. 
DISCUSSION 
VicK is essential in B. subtilis [2] and S. aureus [3] but 
not in S. pneumoniae [7], S. mutans [8], and S. pyogenes [6]. 
We successfully deleted the vicK gene of S. equi. Thus, 
VicK is not essential in S. equi. However, the vicK mutant 
is attenuated in virulence in both mouse models of subcuta-
neous and intranasal S. equi infections, indicating that 
VicRK is important to virulence. The results provide the 
further evidence for the importance of VicRK to virulence of 
Gram-positive pathogens. 
S. equi vicK mutant does not grow as well as the wild-
type strain in both THY and blood, suggesting that the vicK 
deletion causes defect in growth, a plausible reason that 
likely contributes to the attenuation of S. equi virulence in 
the mouse infection models. This suggestion is further sup-
ported by the observations that both the wild-type and vicK 
mutant strains are resistant to phagocytosis by PMNs, which 
suggest that VicRK is not required for the evasion of S. equi 
to the innate immunity. As introduced earlier, the various 
phenotypes have been described for the vicRK mutants of the 
various pathogens. Whether the phenotypes are specific to 
particular organisms is not known. The phenotypes of the S. 
equi vicK mutant are similar to those of the S. pyogenes 
vicK mutant [6], suggesting that the growth defect pheno-
type may be a common feature of the vicRK mutants of vari-
ous Gram-positive pathogens.  
The vicK mutant appears to possess the properties of a 
potential live vaccine. First, it is attenuated in virulence in 
the mouse infection models. Secondly, vicK inoculation 
protects mice against subsequent infection with wild-type S. 
equi. Thirdly, most of the mice with intranasal vicK infec-
tion produce mucosal IgA and systemic IgG specific to pro-
tective antigen SeM. However, whether vicK can be an 
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effective live vaccine and whether the vicK mutant has any 
advantages over the current live S. equi vaccine require the 
test of the mutant in horses since S. equi does not naturally 
infect mice. We hope to perform this expensive test in future 
when funds are available.  
ACKNOWLEDGEMENTS 
This work was supported by grants from the NRI Com-
petitive Grants Program of the U.S. Department of Agricul-
ture (grant no. 2006-01690 and 2007-35204-18306) and P20 
RR-020185 from the National Center for Research Re-
sources, and the Montana State University Agricultural Ex-
perimental Station and USDA Formula Funds.  
REFERENCES 
[1]  Hoch JA. Two-component and phosphorelay signal transduction. 
Curr Opin Microbiol 2000; 3(2): 165-70. 
[2]  Fabret C, Hoch JA. A two-component signal transduction system 
essential for growth of Bacillus subtilis: Implications for anti-
infective therapy. J Bacteriol 1998; 180(23): 6375-83. 
[3]  Martin PK, Li T, Sun D, Biek DP, Schmid MB. Role in cell perme-
ability of an essential two-component system in Staphylococcus 
aureus. J Bacteriol 1999; 181(12): 3666-73. 
[4]  Lange R, Wagner C, de Saizieu A, et al. Domain organization and 
molecular characterization of 13 two-component systems identified 
by genome sequencing of Streptococcus pneumoniae. Gene 1999; 
237(1): 223-34. 
[5]  Throup JP, Koretke KK, Bryant AP, et al. A genomic analysis of 
two-component signal transduction in Streptococcus pneumoniae. 
Mol Microbiol 2000; 35(3): 566-76. 
[6]  Liu M, Hanks TS, Zhang J, et al. Defects in ex vivo and in vivo 
growth and sensitivity to osmotic stress of group A Streptococcus 
caused by interruption of response regulator gene vicR. Microbio-
logy 2006; 152(Pt 4): 967-78. 
[7]  Kadioglu A, Echenique J, Manco S, Trombe MC, Andrew PW. The 
MicAB two-component signaling system is involved in virulence 
of Streptococcus pneumoniae. Infect Immun 2003; 71(11): 6676-9.  
[8]  Senadheera MD, Guggenheim B, Spatafora GA, et al. A VicRK 
signal transduction system in Streptococcus mutans affects gtfBCD, 
gbpB, and ftf expression, biofilm formation, and genetic competen-
ce development. J Bacteriol 2005; 187(12): 4064-76. 
[9]  Ng WL, Kazmierczak KM, Winkler ME. Defective cell wall 
synthesis in Streptococcus pneumoniae R6 depleted for the essenti-
al PcsB putative murein hydrolase or the VicR (YycF) response re-
gulator. Mol Microbiol 2004; 53(4): 1161-75. 
[10]  Echenique JR, Trombe MC. Competence repression under oxygen 
limitation through the two-component MicAB signal-transducing 
system in Streptococcus pneumoniae and involvement of the PAS 
domain of MicB. J Bacteriol 2001; 183(15): 4599-608. 
[11]  Mohedano ML, Overweg K, de la Fuente A, et al. Evidence that 
the essential response regulator YycF in Streptococcus pneumoniae 
modulates expression of fatty acid biosynthesis genes and alters 
membrane composition. J Bacteriol 2005; 187(7): 2357-67. 
[12]  Timoney JF. Strangles. Vet Clin North Am Equine Pract 1993; 
9(2): 365-74. 
[13]  Harrington DJ, Sutcliffe IC, Chanter N. The molecular basis of 
Streptococcus equi infection and disease. Microbes Infect 2002; 
4(4): 501-10. 
[14]  Mukhtar MM, Timoney JF. Chemotactic response of equine poly-
morphonucelar leucocytes to Streptococcus equi. Res Vet Sci 1988; 
45(3-4): 225-9. 
[15]  Timoney JF. The pathogenic equine streptococci. Vet Res 2004; 
35(4): 397-409. 
[16]  Timoney JF, Artiushin SC, Boschwitz JS. Comparison of the se-
quences and functions of Streptococcus equi M-like proteins SeM 
and SzPSe. Infect Immun 1997; 65(9): 3600-5. 
[17]  Anzai T, Timoney JF, Kuwamoto Y, Fujita Y, Wada R, Inoue T. In 
vivo pathogenicity and resistance to phagocytosis of Streptococcus 
equi strains with different levels of capsule expression. Vet Micro-
biol 1999; 67 (4): 277-86. 
[18]  Woolcock JB. Immunity to S. equi. Aust Vet J 1975; 51(12): 554-9. 
[19]  Hanks TS, Liu M, McClure MJ, Lei B. ABC transporter FtsABCD 
of Streptococcus pyogenes mediates uptake of ferric ferrichrome. 
BMC Microbiol 2005; 5:62. 
[20]  White-Owen C, Alexander JW, Sramkoski RM, Babcock GF. Ra-
pid whole-blood microassay using flow cytometry for measuring 
neutrophil phagocytosis. J Clin Microbiol 1992; 30(8): 2071-6. 
[21]  Lei B, Liu M, Chesney GL, Musser JM. Identification of new can-
didate vaccine antigens made by Streptococcus pyogenes: Purifica-
tion and characterization of 16 putative extracellular lipoproteins. J 
Infect Dis 2004; 189(1): 79-89. 
 
 
 
Received: May 22, 2008  Revised: June 06, 2008  Accepted: June 09, 2008 
 
© Liu et al.; Licensee Bentham Open. 
This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.5/), which 
permits unrestrictive use, distribution, and reproduction in any medium, provided the original work is properly cited. 
 